Q2 2026 Earnings Call Transcript November 10, 2025 Immunovant, Inc. misses on earnings expectations. Reported EPS is ...

Q2 2026 Earnings Call Transcript November 10, 2025 Roivant Sciences Ltd. beats earnings expectations. Reported EPS is ...

Roivant Sciences Ltd.'s innovative model and breakthrough autoimmune drug pipeline make it a strong buy. Click here to read ...

Tanvi Lodhia’s path to pharma marketing may sound familiar to her peers in the industry: Like many of them, for example, she ...

Study in uncontrolled Graves’ disease (GD) patients treated for 24 weeks showed first-ever potentially disease-modifying outcome with six-month off-treatment dataIMVT-1402 development is progressing ...

Immunovant posts a wider Q2 loss as R&D spending rises, but progress on IMVT-1402 and batoclimab fuels its pipeline momentum.

Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided a business update.

Merck & Co. is buying the developer of an experimental antiviral drug designed to prevent the flu, as the drugmaker aims to ...

Cidara Therapeutics, Inc. surges to $217 on a bid by Merck & Co., Inc. valuing shares at $221.50. Learn more about CDTX stock ...

Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, the companies said on Friday, gaining access to an experimental drug for flu prevention.

Cidara Therapeutics shares jumped over 42% in after-hours trading following a 13D filing and Phase 3 enrollment milestone.

On November 10, 2025, the Department of Defense’s (“DoD”) final rule amending the Defense Federal Acquisition Regulation Supplement (“DFARS”) ...